BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
See today's BioWorld
Home
» Vertex, Merck Form Potential $384M Cancer Deal For VX-680
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Vertex, Merck Form Potential $384M Cancer Deal For VX-680
June 23, 2004
By
Karen Carey
No Comments
In a deal potentially worth $384 million for Vertex Pharmaceuticals Inc., the company entered a global collaboration with Merck & Co. Inc. to develop and commercialize the former's lead aurora kinase inhibitor, VX-680. (BioWorld Today)
BioWorld